Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice
- PMID: 30650377
- PMCID: PMC6512335
- DOI: 10.1016/j.immuni.2018.12.015
Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice
Abstract
Microbiota are thought to influence the development and progression of inflammatory bowel disease (IBD), but determining generalizable effects of microbiota on IBD etiology requires larger-scale functional analyses. We colonized germ-free mice with intestinal microbiotas from 30 healthy and IBD donors and determined the homeostatic intestinal T cell response to each microbiota. Compared to microbiotas from healthy donors, transfer of IBD microbiotas into germ-free mice increased numbers of intestinal Th17 cells and Th2 cells and decreased numbers of RORγt+ Treg cells. Colonization with IBD microbiotas exacerbated disease in a model where colitis is induced upon transfer of naive T cells into Rag1-/- mice. The proportions of Th17 and RORγt+ Treg cells induced by each microbiota were predictive of human disease status and accounted for disease severity in the Rag1-/- colitis model. Thus, an impact on intestinal Th17 and RORγt+ Treg cell compartments emerges as a unifying feature of IBD microbiotas, suggesting a general mechanism for microbial contribution to IBD pathogenesis.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
DECLARATION OF INTERESTS
D.G. and A.D. are employees of Janssen Research & Development LLC. J.B. is on the scientific advisory boards of Prolacta Bioscience, Inc. and Janssen Research & Development LLC. J.J.F. is on the scientific advisory board of Vedanta and is a consultant for Janssen Research & Development LLC.
Figures
Comment in
-
Defining Dysbiosis in Inflammatory Bowel Disease.Immunity. 2019 Jan 15;50(1):8-10. doi: 10.1016/j.immuni.2018.12.028. Immunity. 2019. PMID: 30650382
-
The gut microbiome: a novel cardio-metabolic target?Cardiovasc Res. 2019 Jul 1;115(9):e82-e84. doi: 10.1093/cvr/cvz151. Cardiovasc Res. 2019. PMID: 31230082 No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
- P30 CA016087/CA/NCI NIH HHS/United States
- T32 DK007180/DK/NIDDK NIH HHS/United States
- R01 CA190400/CA/NCI NIH HHS/United States
- F30 DK108487/DK/NIDDK NIH HHS/United States
- UL1 TR000124/TR/NCATS NIH HHS/United States
- P30 CA016042/CA/NCI NIH HHS/United States
- R01 GM108505/GM/NIGMS NIH HHS/United States
- F31 DK112679/DK/NIDDK NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- U24 AI118644/AI/NIAID NIH HHS/United States
- P30 DK041301/DK/NIDDK NIH HHS/United States
- R01 DK085691/DK/NIDDK NIH HHS/United States
- P01 DK046763/DK/NIDDK NIH HHS/United States
- P50 AT008661/AT/NCCIH NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
